Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,194 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal Saline Placebo Clear all
Completed Not applicable Interventional

Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain

NCT00667264
View directory record Official record
Conditions
Amputation, Phantom Limb, Stump Pain
Interventions
perineural ropivacaine
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 19, 2026, 10:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Not applicable Interventional Results available

Prevention of Post Operative Bone Loss in Children

NCT00655681
View directory record Official record
Conditions
Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions
pamidronate, saline
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
4 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Paracervical Block During Office Hysteroscopy

NCT00811187
View directory record Official record
Conditions
Paracervical Block
Interventions
Lidocaine paracervical block, Normal Saline
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of TAP Block in Cesarean Section Patients

NCT03493828
View directory record Official record
Conditions
Pain Control
Interventions
TAP block using Bupivacaine 0.5%, TAP block using Bupivacaine 0.25%, TAP block using Normal Saline
Procedure
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 19, 2026, 10:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy

NCT02025634
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Acetaminophen, Placebo (0.9% Normal Saline infusion)
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

NCT02989571
View directory record Official record
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Results available

Maxigesic IV Phase 3 Bunionectomy Study

NCT02689063
View directory record Official record
Conditions
Post Operative Pain
Interventions
Maxigesic IV, IV Acetaminophen, IV Ibuprofen, Placebo IV
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pasadena, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine Efficacy Trial

NCT03090191
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
17,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
220
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

Continuous Erector Spinae Plane Blocks to Treat Pain Following Percutaneous Nephrolithotomy

NCT05121168
View directory record Official record
Conditions
Pain, Acute Postoperative, Renal Stone
Interventions
Active bupivacaine 0.25% via an erector spinae plane perineural catheter, Placebo normal saline via an erector spinae plane perineural catheter
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 2Phase 3 Interventional

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

NCT00933868
View directory record Official record
Conditions
Stroke
Interventions
Magnesium Chloride, Placebo
Drug
Lead sponsor
Relox Medical, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions
pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 10:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2

NCT02704325
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
rAAVrh74.MCK.GALGT2, PLACEBO (Saline)
Biological · Other
Lead sponsor
Kevin Flanigan
Other
Eligibility
9 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 2 Interventional

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

NCT04844840
View directory record Official record
Conditions
Keloid
Interventions
STP705, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 19, 2026, 10:16 AM EDT
Recruiting Phase 4 Interventional

Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery

NCT05029726
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Spondylolisthesis, Lumbar Spondylosis, Lumbar Radiculopathy, Lumbar Spine Instability, Synovial Cyst, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Intervertebral Discs
Interventions
Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine, normal saline
Drug
Lead sponsor
John O'Toole
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 19, 2026, 10:16 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders

NCT02824627
View directory record Official record
Conditions
Mood Disorder, Disruptive Behavior Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 19, 2026, 10:16 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

NCT07219654
View directory record Official record
Conditions
Partial Thickness Rotator Cuff Tears
Interventions
TPX-115, Cryopreserving hyaluronic acid medium, Saline
Biological · Other · Drug
Lead sponsor
Tego Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 19, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

NCT03382405
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, mRNA-1443, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Hollywood, Florida • Meridian, Idaho • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 19, 2026, 10:16 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling

NCT02591888
View directory record Official record
Conditions
Pain
Interventions
Placebo, Liposomal bupivacaine
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 19, 2026, 10:16 AM EDT